Sign in →

Test Code 13ACT Coagulation Factor XIII (13) Activity Assay, Plasma


Ordering Guidance


Coagulation testing is highly complex, often requiring the performance and correlation of factor XIII activity with multiple assays and correlation with clinical information. For that reason, if indicated, consider ordering ALBLD / Bleeding Diathesis Profile, Limited, Plasma.



Specimen Required


Patient Preparation:

1. Fasting: 8 hours, preferred but not required

2. It is best to perform this study pre-plasma transfusion if possible. If patient has been recently transfused, wait at least 48 hours after transfusion before collecting the specimen.

3. Specimen should be collected prior to factor replacement therapy.

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL Platelet-poor plasma

Collection Instructions:

1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.

2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

3. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.

4. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results.

2. Each coagulation assay requested should have its own vial.


Useful For

Measuring factor XIII activity

Method Name

Fluorescence-Based Enzyme Activity

Reporting Name

Factor XIII(13) Activity, P

Specimen Type

Plasma Na Cit

Specimen Minimum Volume

Platelet-poor plasma: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma Na Cit Frozen 180 days

Reference Values

≥55%

Interpretation

Decreased factor XIII (FXIII) activity could reflect acquired conditions (eg, autoimmune conditions [systemic lupus erythematosus, rheumatoid arthritis, malignancy, monoclonal gammopathy of undetermined significance, medication-isoniazid], increased consumption [surgery, disseminated intravascular coagulation/intravascular coagulation and fibrinolysis, inflammatory bowel disease, Henoch-Schonlein purpura, sepsis, thrombosis], decreased synthesis [liver disease, leukemia, medication-valproic acid and tocilizumab]), autoantibodies to FXIII, or a congenital deficiency state.

 

Normal FXIII activity makes a congenital or acquired FXIII deficiency less likely. Individuals with heterozygous FXIII-A deficiency have FXIII activity between 30% and 70% and are generally considered to be asymptomatic. However, several studies have reported severe bleeding in affected individuals.

 

Recent transfusion of plasma, cryoprecipitate, or FXIII concentrate will raise FXIII levels and may mask a diagnosis of FXIII deficiency.

Clinical Reference

1. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. 1999;107(3):468-484

2. Kottke-Marchant K. Performance and interpretation of routine coagulation assays. In: Laboratory Hematology Practice. Wiley Blackwell Publishing; 2012:420-434

3. Hoffman R, Benz EJ Jr, Siberstein LE, et al. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018

4. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9(7):1404-1406

5. Al Sharif MA, Mathews N, Tasneem S, et al. Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on  consecutive samples and patients. Res Pract Thromb Haemost. 2025;9(1):102689

6. Dorgalaleh A, Jozdani S, Zadeh MK. Factor XIII deficiency: Laboratory, molecular, and clinical aspects. Semin Thromb Hemost. 2025;51(2):155-169. doi:10.1055/s-0044-1796673

Day(s) Performed

Monday through Friday

Report Available

1 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

85290

LOINC Code Information

Test ID Test Order Name Order LOINC Value
13ACT Factor XIII(13) Activity, P In Process

 

Result ID Test Result Name Result LOINC Value
623415 Factor XIII (13) Activity, P In Process

Forms

If not ordering electronically, complete, print, and send an Coagulation Test Request (T753) with the specimen.